Tuesday, May 17, 2022

Ardelyx, Inc. (ARDX) Stock on a Gaining Trajectory, Here’s the Reason

Ardelyx, Inc., a biopharmaceutical company, closed Monday’s regular session at $1.17 after surging 9.35% during the day. In the premarket session, ARDX stock further gained an increase of 5.98% and was trading at $1.24 at the last check.


Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .

Sponsored


ARDX Launched IBSRELA

ARDX stock is on the rise following the launch of IBSRELA. Ardelyx announced on Monday that it would be launching IBSRELA, which is the only NHE3 inhibitor for treating Irritable Bowel Syndrome with Constipation. The approval of the drug is based on a set of successful phase 3 trials that involved more than 1200 patients having Irritable Bowel Syndrome. Both trials were able to meet their primary endpoints. IBSRELA is the first product of Ardelyx that is approved by the FDA.

Biopharma Industry Having Smooth Ride


A Backdoor Way To Profit From Today’s Crypto Bull Market

Even if you’re not actively in crypto, you deserve to know what’s actually going on...

Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.

Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .

Sponsored


Biopharmaceutical companies are long been considered among the most stable companies concerning investments, hence considered among the fastest-growing sectors. With the pandemic making us realize the importance of the healthcare system and medication products, the role of pharmaceutical companies has been on a rise. This ultimately is forcing the investors to jump the ships from other sectors toward pharma.

What Could Happen with ARDX?

Since its IPO, ARDX has plunged more than 91%. However, during the last month of 2021, ARDX announced that it would be launching IBSRELA sometime in 2022. Since then, investors are flocking in to buy the stock. The company hopes that IBSRELA would generate annual revenue of more than $500 million, making the company’s financial position stronger than ever before.

Final Remarks

Looking ahead, the best strategy for the investor community is to invest for a longer period in ARDX stock instead of a short investment, which could prove to be a tricky scenario for them. Sure IBSRELA launch would provide an opportunity for investors to improve their returns, but this would not be the case in the immediate future. Hence, the best way to extract solid returns from the ARDX is via long-term investment.

Latest news

A Few Bright Spots in Tesla Inc. (TSLA)

Tesla's (TSLA) Shanghai facility ceased operations on Monday owing to material shortages, according to Reuters. Furthermore, demand for Tesla electric vehicles decreased drastically in...

A Closer Look at DocuSign Inc.’s (DOCU) Growth Curve

DocuSign Inc. (NASDAQ: DOCU), a software firm that creates an electronic signature and verification solutions, is presently trading more than 70% below its 52-week...

One Of The Good Ones: Enphase Energy Inc. (ENPH)

Enphase Energy, Inc. (NASDAQ: ENPH), a maker of inverters, released its first-quarter 2022 results. Enphase set a new sales record and outperformed Wall Street...

Riding the Trend or Protecting Profits | AT&T Inc. (T)

AT&T Inc. (NYSE: T), a telecommunications service provider, released its first-quarter earnings last week. The firm claimed a record number of new communication subscribers,...

Related news

A Few Bright Spots in Tesla Inc. (TSLA)

Tesla's (TSLA) Shanghai facility ceased operations on Monday owing to material shortages, according to Reuters. Furthermore, demand for Tesla electric vehicles decreased drastically in...

A Closer Look at DocuSign Inc.’s (DOCU) Growth Curve

DocuSign Inc. (NASDAQ: DOCU), a software firm that creates an electronic signature and verification solutions, is presently trading more than 70% below its 52-week...

One Of The Good Ones: Enphase Energy Inc. (ENPH)

Enphase Energy, Inc. (NASDAQ: ENPH), a maker of inverters, released its first-quarter 2022 results. Enphase set a new sales record and outperformed Wall Street...

Riding the Trend or Protecting Profits | AT&T Inc. (T)

AT&T Inc. (NYSE: T), a telecommunications service provider, released its first-quarter earnings last week. The firm claimed a record number of new communication subscribers,...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

1745

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam